Mexidol, a Russian prescription medicine pairing a vitamin B6-related antioxidant with a cell-energy compound, is used mainly for stroke, brain blood-flow disease and anxiety. Courses were linked to better stroke recovery, small, inconsistent thinking gains, and less anxiety and fatigue. Side effects resembled placebo, but it can strengthen sedatives; long-term safety is unknown. Most placebo-controlled trials were manufacturer-funded. Unproven in healthy adults; slower aging rests on animal studies alone. (Full Review)
| Marker | Target | Why |
|---|---|---|
| ALT | 7–56 U/L (standard reference range) | Safety check; rise stops use |
| AST | 10–40 U/L (standard reference range) | Safety check; rise stops use |
| Serum creatinine | 0.6–1.3 mg/dL (standard reference range) | Safety check; rise stops use |
| LDL cholesterol | No established target for this use; track change from own baseline | Expected to change (label claim) |
| Montreal Cognitive Assessment score | No established target; track change from own baseline | Expected to change |
| Anxiety questionnaire score | Track change from own baseline | Expected to change |
Cadence: Baseline before a first course; liver and kidney tests at 4 weeks and course end; lipids at course end; cognitive and anxiety scores at course end and before any repeat course (typically every 6–12 months); allergy symptoms and drowsiness daily in week one